Belgium-based AI company icometrix has received a CPT III code from the American Medical Association, allowing reimbursement for its FDA-cleared brain MRI quantification software. The software provides metrics for cerebral MRI scans to aid clinicians in diagnosing and monitoring neurological conditions such as Alzheimer’s disease, multiple sclerosis, and Parkinson’s disease. This code will enable healthcare professionals to report the use of icometrix software as a practice expense. icometrix previously received $18 million in funding in 2019 and has been awarded grants for research in Parkinson’s disease and multiple sclerosis imaging. Another company, Neurophet, uses AI software for diagnosing brain disorders.
July 4, 2023
Artificial Intelligence
FDAcop
